Axogen Lifts Full-Year Growth Target to 24%+ as Q2 Revenue Surges 23%
AXGN has more than doubled off its 52-week low of $12.385 on elevated volume (2.1× avg).
Summary
Axogen posted Q2 revenue of $69.7M (+23.1% YoY) and raised its full-year revenue growth guidance to at least 24%, while operating expenses pushed the quarter to a small loss. The balance sheet is debt-free with $111M in cash and investments.
Key Events · Earnings and Guidance · AXGN
-
Revenue Growth Accelerates
Driven by higher unit volumes and pricing across all markets, Q2 2026 revenue reached $69.7 million, a 23.1% increase over the prior year.
-
Full-Year Guidance Raised
Management now expects full-year revenue growth of at least 24%, up from prior guidance, reflecting broad-based demand and expanding account productivity.
-
Gross Margin Pressure
Gross margin declined to 72.7% from 74.2% a year ago, primarily due to higher costs for biologic Avance products and increased sales of longer grafts.
-
Balance Sheet Transformed
Cash and investments totaled $111.4 million at quarter-end, with all long-term debt eliminated following a $133 million equity raise in January 2026.
Analysis · AXGN · Industrial Applications And Services
A strong second quarter saw revenue climb 23% to $69.7 million, fueled by higher unit volumes and improved pricing. Reflecting confidence in sustained demand across its nerve repair portfolio, the company raised its full-year revenue growth guidance to at least 24%. Gross margin edged down to 72.7% on higher product costs, but the balance sheet is dramatically stronger after a January equity raise paid off all debt, leaving $111 million in cash and investments. Spending on sales, R&D, and stock compensation grew faster than revenue, pushing the quarter to a small operating loss. The subsequent $7 million investment in Trace Biosciences adds a strategic growth option in nerve imaging.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AXGN was trading at $41.37 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $12.39 to $46.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.